ACTA1 and Hepatic fibrosis: Given the central role of αSMA and deposited collagen in driving tissue fibrosis35,36 and the observed dose-dependent reduction of these markers by PZQ treatment, although not significantly, our experiments in this model of acute, CCl4-induced liver fibrosis suggest a certain, but minimal, potential of PZQ in limiting the onset of tissue fibrosis when administered twice daily for three weeks prior to establishment of tissue fibrosis in an acute model.